Cargando…
Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions
Chimeric antigen receptor modified T cells (CAR-T) have yielded impressive clinical outcomes in treating hematopoietic malignancies. However, relapses have occurred in a substantial number of patients and limited the development of CAR-T therapy. Most underlying reasons for these relapses can be att...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318076/ https://www.ncbi.nlm.nih.gov/pubmed/32636832 http://dx.doi.org/10.3389/fimmu.2020.01046 |